Q3 2023 13F Holders as of 9/30/2023
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
226M
-
Number of holders
-
149
-
Total 13F shares, excl. options
-
129M
-
Shares change
-
-2.78M
-
Total reported value, excl. options
-
$408M
-
Value change
-
-$15.7M
-
Put/Call ratio
-
7.07
-
Number of buys
-
78
-
Number of sells
-
-62
-
Price
-
$3.17
Significant Holders of Allogene Therapeutics, Inc. - Common Stock (ALLO) as of Q3 2023
184 filings reported holding ALLO - Allogene Therapeutics, Inc. - Common Stock as of Q3 2023.
Allogene Therapeutics, Inc. - Common Stock (ALLO) has 149 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 129M shares
of 226M outstanding shares and own 56.93% of the company stock.
Largest 10 shareholders include FMR LLC (25.1M shares), TPG GP A, LLC (18.7M shares), VANGUARD GROUP INC (10.6M shares), BlackRock Inc. (8.89M shares), STATE STREET CORP (8.2M shares), JPMORGAN CHASE & CO (6.91M shares), Woodline Partners LP (5.31M shares), PRIMECAP MANAGEMENT CO/CA/ (5.28M shares), EcoR1 Capital, LLC (4.49M shares), and CITADEL ADVISORS LLC (4.12M shares).
This table shows the top 149 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.